MSMD Protocol
Metformin · Statin · Mebendazole · Doxycycline
Four inexpensive, well-tolerated drugs repurposed to simultaneously block multiple cancer hallmarks. Developed by the Care Oncology Clinic (COC) in London. Supported by the METRICS Trial.
Metformin
Atorvastatin
Mebendazole
Doxycycline
METRICS Trial
Clinical evidence
Important: This protocol uses prescription medications. Always consult your oncologist before starting. Doses must be individualised. This information is for educational purposes only.
Why Combine 4 Drugs?
Cancer is genetically unstable — it evolves resistance to single-drug treatments by activating alternative survival pathways. The MSMD protocol attacks multiple hallmarks of cancer simultaneously:
Metformin
Starves cancer cells of energy via AMPK/mTOR
Statin
Blocks cholesterol + RAS membrane signalling
Mebendazole
Disrupts cancer cell division via tubulin
Doxycycline
Eliminates resistant cancer stem cells
Cancer Pathways Targeted
PI3K / AKT / mTOR
Metformin
KRAS / RAS activation
Atorvastatin
VEGF / Angiogenesis
Atorvastatin + Doxycycline
Tubulin / Mitosis
Mebendazole
Cancer Stem Cells
Doxycycline
NF-κB Inflammation
Doxycycline + Atorvastatin
Insulin / IGF-1 axis
Metformin
p53 tumour suppressor
Mebendazole
The Four Drugs
Mechanism of Action
Activates AMPK — the cell's 'energy sensor'. This blocks mTOR (growth signal), reduces glucose uptake by tumour cells, and lowers insulin/IGF-1 levels that fuel cancer growth.
Pathways Targeted
Typical Dose (Protocol Reference)
500–2000 mg/day (divided doses with food)
Evidence Base
Epidemiological: diabetics on metformin have 30–40% lower cancer incidence. Phase II trials ongoing.
Cautions
- Avoid in renal impairment (eGFR < 30)
- Lactic acidosis risk in severe illness
- May reduce B12 absorption
- Hold before IV contrast dye
Evidence Base
🔬 METRICS Trial
The METRICS Trial (Metformin, Atorvastatin, Mebendazole + standard care) led by the Care Oncology Clinic in the UK is one of the first clinical trials evaluating this combination. Initial data suggests improved outcomes with acceptable safety.
📊 Epidemiological Foundation
Large-scale studies consistently show cancer patients who happen to be on these drugs (for diabetes, cholesterol, parasites) have significantly better outcomes. This 'repurposing signal' is what drove the COC concept.
🧬 Multi-Pathway Rationale
Cancer evolves around single-drug blockades. The MSMD combination simultaneously targets multiple hallmarks — metabolism, angiogenesis, stem cells, and proliferation — making escape harder.
Learn More
Informational only. Not medical advice. Always consult your oncologist before adopting any protocol.